226 related articles for article (PubMed ID: 31276666)
21. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
22. The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice.
Hutch CR; Roelofs K; Haller A; Sorrell J; Leix K; D'Alessio DD; Augustin R; Seeley RJ; Klein T; Sandoval DA
Diabetologia; 2019 Oct; 62(10):1928-1937. PubMed ID: 31414143
[TBL] [Abstract][Full Text] [Related]
23. Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
Hirano T; Yamashita S; Takahashi M; Hashimoto H; Mori Y; Goto M
Metabolism; 2016 Jun; 65(6):893-903. PubMed ID: 27173468
[TBL] [Abstract][Full Text] [Related]
24. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
[TBL] [Abstract][Full Text] [Related]
25. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
Kim KR; Rhee SD; Kim HY; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
Eur J Pharmacol; 2005 Jul; 518(1):63-70. PubMed ID: 16106524
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Kim SH; Jung E; Yoon MK; Kwon OH; Hwang DM; Kim DW; Kim J; Lee SM; Yim HJ
Eur J Pharmacol; 2016 Oct; 788():54-64. PubMed ID: 27298192
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE
J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice.
Nonogaki K; Kaji T
Diabetes Metab; 2015 Nov; 41(5):425-8. PubMed ID: 26234524
[TBL] [Abstract][Full Text] [Related]
29. Anagliptin increases insulin-induced skeletal muscle glucose uptake via an NO-dependent mechanism in mice.
Sato H; Kubota N; Kubota T; Takamoto I; Iwayama K; Tokuyama K; Moroi M; Sugi K; Nakaya K; Goto M; Jomori T; Kadowaki T
Diabetologia; 2016 Nov; 59(11):2426-2434. PubMed ID: 27525648
[TBL] [Abstract][Full Text] [Related]
30. Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner.
Esser N; Barrow BM; Choung E; Shen NJ; Zraika S
Islets; 2018; 10(5):175-180. PubMed ID: 30142012
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor.
Jain MR; Joharapurkar AA; Bahekar RH; Patel H; Jadav P; Kshirsagar SG; Patel VJ; Patel KN; Ramanathan VK; Patel PR; Desai RC
J Diabetes; 2015 Sep; 7(5):708-17. PubMed ID: 25327540
[TBL] [Abstract][Full Text] [Related]
32. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
33. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors.
Hansotia T; Baggio LL; Delmeire D; Hinke SA; Yamada Y; Tsukiyama K; Seino Y; Holst JJ; Schuit F; Drucker DJ
Diabetes; 2004 May; 53(5):1326-35. PubMed ID: 15111503
[TBL] [Abstract][Full Text] [Related]
34. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice.
Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
Pharmacology; 2009; 83(3):177-87. PubMed ID: 19176982
[TBL] [Abstract][Full Text] [Related]
36. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Deacon CF
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
[TBL] [Abstract][Full Text] [Related]
37. DPP-4 inhibition increases GIP and decreases GLP-1 incretin effects during intravenous glucose tolerance test in Wistar rats.
Freyse EJ; Berg S; Kohnert KD; Heinke P; Salzsieder E
Biol Chem; 2011 Mar; 392(3):209-15. PubMed ID: 21281062
[TBL] [Abstract][Full Text] [Related]
38. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
Holst JJ; McGill MA
Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
[TBL] [Abstract][Full Text] [Related]
39. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
Green JB
Postgrad Med; 2012 Jul; 124(4):54-61. PubMed ID: 22913894
[TBL] [Abstract][Full Text] [Related]
40. Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure.
Takahashi A; Ihara M; Yamazaki S; Asanuma H; Asakura M; Kitakaze M
Int Heart J; 2015; 56(4):372-6. PubMed ID: 26104180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
